Live Breaking News & Updates on Hyloris Announces Launch

Stay updated with breaking news from Hyloris announces launch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV in the U.S. and approval In Canada

Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV in the U.S. and approval In Canada
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Stijn Van Rompay , Jean Luc Vandebroek , Jessica Mchargue , Hikma Pharmaceuticals , Hyloris Pharmaceuticals , Investor Relations Communications , Hyloris Pharmaceuticals Sa Euronext Brussels , Health Canada , Hyloris Announces Launch , Potent Non Opioid Painkiller , Tradename Combogesic , Euronext Brussels , Van Rompay , Chief Executive Officer , Pabout Hyloris Pharmaceuticals , Luc Vandebroek , Investor Relations , Data Analysis ,

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Maxigesic® IV, a Potent Non-opioid Painkiller, Marketed in the U.S. under the Tradename Combogesic® IVMaxigesic® IV. ....

Stijn Van Rompay , Jean Luc Vandebroek , Jessica Mchargue , Health Canada , Hyloris Pharmaceuticals Sa Euronext Brussels , Hikma Pharmaceuticals , Investor Relations Communications , Hyloris Pharmaceuticals , Hyloris Announces Launch , Potent Non Opioid Painkiller , Tradename Combogesic , Euronext Brussels , Van Rompay , Chief Executive Officer , Pabout Hyloris Pharmaceuticals , Luc Vandebroek , Investor Relations , Data Analysis ,

Investegate |Hyloris Pharmaceuticals SA Announcements | Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic® IV, a Novel Non-Opioid Pain Treatment, in Key European Markets

Hyloris Pharmaceuticals
SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Maxigesic IV is now available in Germany, the largest European pharmaceutical market, and Austria.
Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion. Hyloris’ partner AFT Pharmaceuticals works together with distribution partners with strong local presence to commercialise the product globally.
Maxigesic IV is currently licensed in more than 100 countries across the globe, and it has been registered in 24 countries. Following the launch in Germany and Austria, the product is now available in 5 countries: Australia, New Zealand, The United Arab Emirates, Germany, and Austria. ....

United Arab Emirates , New Zealand , Marieke Vermeersch , Stijn Van Rompay , Hyloris Pharmaceuticals Sa Euronext Brussels , Pabout Hyloris Pharmaceuticals , Hyloris Pharmaceuticals , Corporate Communications , Hyloris Announces Launch , Novel Non Opioid Pain Treatment , Key European , Euronext Brussels , Van Rompay , Chief Executive Officer , Kever Pharma , Pain Market Insights , Market Forecast , ஒன்றுபட்டது அரபு அமீரகங்கள் , புதியது ஜீலாந்து , பெருநிறுவன தகவல்தொடர்புகள் , விசை ஐரோப்பிய , தலைமை நிர்வாகி அதிகாரி , எப்போதும் பார்மா , வலி சந்தை நுண்ணறிவு , சந்தை முன்னறிவிப்பு ,